Studies have shown that mutations in the BCL-2 and BAX proteins are frequently detected in several types of cancers, suggesting that they play crucial roles in elucidating molecular mechanisms driving oncogenic transformation (13) and drug resistance (14). This evidence concerns the gene BCL2 and cancer.